Clinical Trials on Advanced MTAP-null Solid Tumors in Sweden

Total 52 results

Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Advanced Solid Tumors

Switzerland, Sweden, Netherlands, United States, United Kingdom
Vall d'Hebron Institute of Oncology
Taisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LP

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

Advanced Solid Tumor

Spain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Advanced Solid Tumors

United States, Germany, Norway, Netherlands, Belgium, Denmark, Sweden, Switzerland
Incyte Corporation

Active, not recruiting

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Advanced Solid Tumors

United States, Sweden, Netherlands, Norway, Denmark
PharmaMar

Completed

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Belgium, France, Italy, Switzerland, Germany, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

cMET Dysegulation Advanced Solid Tumors

Austria, Denmark, Sweden, United Kingdom, Spain, Germany, Netherlands, United States
Axelar AB

Completed

A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

Solid Tumors

Sweden
Merck Sharp & Dohme LLC

Completed

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

Advanced Solid Tumors

United States, Australia, Canada, Chile, China, France, Greece, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, South Africa, Spain, Sweden
Uppsala University Hospital

Recruiting

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (MEGALiT)

Solid Tumor

Sweden
Alligator Bioscience AB

Completed

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

Neoplasms | Solid Tumor

Sweden
Alligator Bioscience AB

Completed

ADC-1013 First-in-Human Study

Neoplasms | Solid Tumors

United Kingdom, Denmark, Sweden
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Lidds AB

Terminated

Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

Solid Tumor

Lithuania, Sweden, Denmark
Alligator Bioscience AB

Completed

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

Neoplasms | Solid Tumor

Denmark, Sweden
University Hospital Heidelberg
German Cancer Research Center

Recruiting

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt)

Solid Tumor | CNS Tumor

France, Germany, Australia, Austria, Sweden, Netherlands, Switzerland
Axelar AB

Completed

A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

Solid Tumors | Hematological Malignancies

Sweden
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors

United States, Taiwan, United Kingdom, Hong Kong, Belgium, France, Spain, China, Netherlands, Poland, Sweden
European Organisation for Research and Treatment...

Completed

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

Netherlands, Sweden, United Kingdom
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
AstraZeneca

Active, not recruiting

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Breast | Prostate | Ovarian | Pancreatic | Advanced Tumours

Sweden, Spain, Israel, Australia, Germany
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Pfizer

Completed

Rollover Protocol for Prior SU011248 Protocols

Solid Tumors

United States, Australia, Italy, Greece, Sweden, Switzerland, United Kingdom, Canada, Singapore, France, Netherlands
European Organisation for Research and Treatment...

Completed

Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care

Unspecified Adult Solid Tumor, Protocol Specific

France, United Kingdom, Belgium, Spain, Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

Poland, Korea, Republic of, United States, Argentina, Australia, Canada, Colombia, France, Germany, Guatemala, Israel, Italy, Japan, Latvia, Mexico, Peru, Puerto Rico, Romania, South Africa, Spain, Sweden, Turkey, Ukraine
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
Azienda Ospedaliera di Perugia

Not yet recruiting

Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients (MELCAYA)

Advanced Melanoma | Early Melanoma

Italy, Sweden, France, Germany, Netherlands, Poland, Spain
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor

France, Germany, Italy, Netherlands, Sweden, United Kingdom, Brazil, Israel, Korea, Republic of, United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

Relapsed or Refractory Solid Tumors

United States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
Bayer

Active, not recruiting

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)

Solid Tumors Harboring NTRK Fusion

United States, China, Poland, Australia, Germany, Japan, Canada, Italy, Czechia, Spain, Turkey, United Kingdom, Sweden, Netherlands, France, Switzerland, Korea, Republic of, Denmark, Ireland, Israel, Ukraine
NantCell, Inc.
Takeda

Terminated

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)

Cancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine Cancer

Italy, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Advanced Melanoma

Canada, United States, Australia, Spain, Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
BioNTech Cell & Gene Therapies GmbH

Recruiting

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Solid Tumor

Australia, Germany, Netherlands, Sweden
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Solid Tumors

Spain, Denmark, Poland, Sweden
AstraZeneca

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

Advanced Solid Malignancies

United States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
CellCentric Ltd.

Recruiting

Study to Evaluate CCS1477 in Advanced Tumours

Advanced Solid Tumors | Metastatic Breast Cancer | Non-small Cell Lung Cancer | Metastatic Castration-Resistant Prostate Cancer

United Kingdom, United States, Netherlands, France, Spain, Sweden
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Helsinki University Central Hospital
Tampere University Hospital

Enrolling by invitation

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study (CardioSwitch)

Solid Tumor

Denmark, Norway, Sweden, Finland, Netherlands, Iceland, Ireland
Bayer

Active, not recruiting

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)

Solid Tumors Harboring NTRK Fusion

United States, Korea, Republic of, China, Japan, India, France, Turkey, Portugal, Spain, Taiwan, Czechia, Sweden, Brazil, Denmark, Singapore, Argentina, Germany, Ireland
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
Cogent Biosciences, Inc.

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic Cancer | Advanced Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Pfizer
Children's Oncology Group (COG)

Active, not recruiting

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Ewing Sarcoma | Medulloblastoma | Rhabdoid Tumor | Neuroblastoma | Solid Tumors | Rhabdomyosarcoma | Diffuse Intrinsic Pontine Glioma

United States, Canada, India, Spain, United Kingdom, Belgium, Hungary, Brazil, Slovakia, Poland, Argentina, Bulgaria, Korea, Republic of, Czechia, Germany, Israel, Netherlands, France, Italy, Sweden, Turkey
Genzyme, a Sanofi Company

Active, not recruiting

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)

Medullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid Cancer

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
Pfizer

Completed

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (STAR-TOR)

Lymphoma, Mantle-Cell | Carcinoma, Renal Cell, Advanced | Gastrointestinal Stroma Tumors

Germany
Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden

Clinical Trials on Advanced MTAP-null Solid Tumors in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations